Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Net Income for 16 consecutive years, with -$141.2 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 2775.18% to -$141.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$220.5 million through Dec 2025, down 1065.79% year-over-year, with the annual reading at -$220.5 million for FY2025, 1066.53% down from the prior year.
  • Net Income hit -$141.2 million in Q4 2025 for Vanda Pharmaceuticals, down from -$22.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $9.6 million in Q2 2021 to a low of -$141.2 million in Q4 2025.
  • Historically, Net Income has averaged -$9.9 million across 5 years, with a median of -$1.1 million in 2023.
  • Biggest five-year swings in Net Income: surged 1856.46% in 2021 and later crashed 3986.13% in 2024.
  • Year by year, Net Income stood at $7.1 million in 2021, then fell by 2.96% to $6.9 million in 2022, then crashed by 134.71% to -$2.4 million in 2023, then crashed by 105.44% to -$4.9 million in 2024, then plummeted by 2775.18% to -$141.2 million in 2025.
  • Business Quant data shows Net Income for VNDA at -$141.2 million in Q4 2025, -$22.6 million in Q3 2025, and -$27.2 million in Q2 2025.